Breast cancer cells exposed to the pro-inflammatory IL-6 cytokine exhibited enhanced invasion capacity and increased drug resistance (Dethlefsen et al., 2013); also, inflammatory microenvironments are known to expand the CSC pool and increase tumor initiation (Shenoy et al., 2012). The gene discussed is IL6; the disease is neoplasm.